Migraine Market to Progress at a CAGR of 10.96% by 2032 | DelveInsight The migraine market is expected to surge due to the increasing prevalence of the disease along with increasing awareness during the forecast period. Furthermore, the launch of various multiple-stage pipeline products will significantly revolutionize the migraine market dynamics. LAS VEGAS , June 15, 2022 |PRNewswire| -- DelveInsight''s Migraine Market Insights report includes a comprehensive understanding of current treatment practices, Migraine emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM ( the United States , the EU5 (the United Kingdom , Italy , Spain , France , and Germany ), and Japan . Key Takeaways from the Migraine Market Report As per DelveInsight analysis, the migraine market size in the 7MM was approximately USD 6.9 billion in 2021. As per the estimates, the total Migraine prevalent cases in the 7MM was approximately 118 million in 2021. Leading Migraine companies such as Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr.